vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs 1.6%, a 46.3% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -21.9%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -15.4%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
PCRX vs RILY — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $188.3M |
| Net Profit | $2.9M | $90.3M |
| Gross Margin | — | 79.5% |
| Operating Margin | 3.9% | 32.3% |
| Net Margin | 1.6% | 47.9% |
| Revenue YoY | 5.0% | -21.9% |
| Net Profit YoY | — | 1710.8% |
| EPS (diluted) | $0.07 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $188.3M | ||
| Q3 25 | $179.5M | $215.3M | ||
| Q2 25 | $181.1M | $188.2M | ||
| Q1 25 | $168.9M | $197.2M | ||
| Q4 24 | $187.3M | $241.0M | ||
| Q3 24 | $168.6M | $225.5M | ||
| Q2 24 | $178.0M | $256.0M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $90.3M | ||
| Q3 25 | $5.4M | $91.1M | ||
| Q2 25 | $-4.8M | $139.5M | ||
| Q1 25 | $4.8M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-143.5M | $-284.4M | ||
| Q2 24 | $18.9M | $-433.6M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 79.5% | ||
| Q3 25 | 80.9% | 83.7% | ||
| Q2 25 | 77.4% | 81.3% | ||
| Q1 25 | 79.7% | 81.4% | ||
| Q4 24 | 78.7% | 79.8% | ||
| Q3 24 | 76.9% | 82.1% | ||
| Q2 24 | 75.1% | 84.5% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 32.3% | ||
| Q3 25 | 3.5% | 30.4% | ||
| Q2 25 | 4.7% | 5.7% | ||
| Q1 25 | 1.2% | -31.2% | ||
| Q4 24 | 13.2% | -69.2% | ||
| Q3 24 | -82.8% | -36.4% | ||
| Q2 24 | 15.9% | -90.8% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 47.9% | ||
| Q3 25 | 3.0% | 42.3% | ||
| Q2 25 | -2.7% | 74.1% | ||
| Q1 25 | 2.8% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -85.1% | -126.1% | ||
| Q2 24 | 10.6% | -169.4% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $2.78 | ||
| Q3 25 | $0.12 | $2.91 | ||
| Q2 25 | $-0.11 | $4.50 | ||
| Q1 25 | $0.10 | $-0.39 | ||
| Q4 24 | $0.38 | $-0.01 | ||
| Q3 24 | $-3.11 | $-9.39 | ||
| Q2 24 | $0.39 | $-14.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $653.9M | $-171.5M |
| Total Assets | $1.2B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $226.6M | ||
| Q3 25 | $246.3M | $184.2M | ||
| Q2 25 | $445.9M | $267.4M | ||
| Q1 25 | $493.6M | $138.3M | ||
| Q4 24 | $484.6M | $146.9M | ||
| Q3 24 | $453.8M | $159.2M | ||
| Q2 24 | $404.2M | $236.9M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $1.4B | ||
| Q3 25 | $376.7M | $1.3B | ||
| Q2 25 | $580.5M | $1.3B | ||
| Q1 25 | $583.4M | $1.4B | ||
| Q4 24 | $585.3M | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $-171.5M | ||
| Q3 25 | $727.2M | $-260.5M | ||
| Q2 25 | $757.8M | $-351.7M | ||
| Q1 25 | $798.5M | $-496.8M | ||
| Q4 24 | $778.3M | $-488.2M | ||
| Q3 24 | $749.6M | $-497.6M | ||
| Q2 24 | $879.3M | $-218.3M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.5B | $2.2B | ||
| Q2 24 | $1.6B | $3.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $26.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $26.2M | ||
| Q3 25 | $60.8M | $-60.6M | ||
| Q2 25 | $12.0M | $-25.6M | ||
| Q1 25 | $35.5M | $184.0K | ||
| Q4 24 | $33.1M | $-2.7M | ||
| Q3 24 | $53.9M | $19.5M | ||
| Q2 24 | $53.2M | $111.5M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | — | ||
| Q3 25 | $57.0M | — | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $26.9M | — | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | $49.8M | — | ||
| Q2 24 | $51.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | — | ||
| Q3 25 | 31.7% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 15.9% | — | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 29.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 0.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.29× | ||
| Q3 25 | 11.20× | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
